Publications
-
August 26, 2022
Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD
Craig Ostroff, Ronald D. Perrone and Frank S. Czerwiec
CJASN August 2022, CJN.05360522; DOI: https://doi.org/10.2215/CJN.05360522 -
August 26, 2022
Perspectives on Drug Development in Early ADPKD
Djalila Mekahli, Hayley Womack and Neera K. Dahl
CJASN August 2022, CJN.05190422; DOI: https://doi.org/10.2215/CJN.05190422 -
August 26, 2022
Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease
Max C. Liebau, Erum A. Hartung and Ronald D. Perrone
CJASN August 2022, CJN.04870422; DOI: https://doi.org/10.2215/CJN.04870422 -
August 26, 2022
Drug Development for Cystic Kidney Diseases
Sorin Fedeles and Ronald D. Perrone
CJASN August 2022, CJN.04910422; DOI: https://doi.org/10.2215/CJN.04910422 -
August 12, 2022
Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies
C-Path’s Type 1 Diabetes Consortium (T1DC) is pleased to announce that “Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies” has been published in Diabetologia. The article reports on the work of the consortium and T1DC’s approach to obtaining regulatory endorsement of a model-based drug development tool.